Spots Global Cancer Trial Database for relapsed
Every month we try and update this database with for relapsed cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | NCT03465891 | Lymphoma | atezolizumab Low- Dose, Loca... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | NCT03218683 | Relapsed or Ref... | AZD5991 AZD5991 + Venet... | 18 Years - 85 Years | AstraZeneca | |
| Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma | NCT03585673 | Esophagus Squam... Metastatic Canc... | Docetaxel-PM Oxaliplatin | 18 Years - | Dong-A University Hospital | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | NCT02568683 | Non-Hodgkin Lym... | Entospletinib Vincristine | 18 Years - | Gilead Sciences | |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | NCT02974647 | Lymphoma | Ruxolitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | NCT01522469 | Relapsed or Ref... | Crenolanib Besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | NCT04070768 | Acute Myeloid L... | Gemtuzumab Ozog... Venetoclax | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | NCT05313243 | T-Cell Lymphoma | Brentuximab ved... Pembrolizumab | 18 Years - | Yale University | |
| TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) | NCT04557436 | B Acute Lymphob... | PBLTT52CAR19 | 6 Months - 18 Years | Great Ormond Street Hospital for Children NHS Foundation Trust | |
| An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | NCT03989336 | Ovarian Cancer | Manganese Chlor... nab-paclitaxel Platinum chemot... Sintilimab | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) | NCT03057990 | Myelodysplastic... | Pyrimethamine | 18 Years - | Montefiore Medical Center | |
| Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | NCT00511238 | Multiple Myelom... | carfilzomib carfilzomib | 18 Years - | Amgen | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | NCT01449344 | Mantle Cell Lym... | Rituximab High dose Ara-C Dexamethasone Bortezomib | 18 Years - | European Mantle Cell Lymphoma Network | |
| iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes | NCT03446638 | Myelodysplastic... | FDA-approved dr... FLAG induction 7 + 3 induction Low-dose cytara... Supportive care... Computational b... | 18 Years - 99 Years | University of Florida | |
| Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02429375 | Hodgkin Lymphom... | Mocetinostat Pl... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma | NCT04864522 | Multiple Myelom... | SLAMF7 FPBMC | 18 Years - | University of Virginia | |
| To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | NCT01199224 | Solid Tumors | veliparib veliparib veliparib veliparib | 18 Years - | AbbVie | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | NCT01121757 | Follicular Lymp... Marginal Zone L... | azacitidine lenalidomide | 18 Years - | Duke University | |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | NCT02003092 | Solid Tumor Triple Negative... | RX-5902 | 18 Years - | Rexahn Pharmaceuticals, Inc. | |
| Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. | NCT04358237 | Small Cell Lung... | Lurbinectedin Pembrolizumab | 18 Years - | Blanco, Dr Antonio Calles MD | |
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | NCT03575351 | Lymphoma, Non-H... | Standard of Car... JCAR017 | 18 Years - 75 Years | Celgene | |
| CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | NCT04034446 | Relapsed or Ref... | CD19-CD22 CAR-T... | 3 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | NCT02417285 | Lymphoma, Large... Lymphoma, Non-H... | Obinutuzumab CC-122 | 18 Years - | Celgene | |
| Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | NCT01460901 | Neuroblastoma | GD2 CAR modifie... | 18 Months - 17 Years | Children's Mercy Hospital Kansas City | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | NCT02686346 | Hodgkin Disease | Brentuximab Ved... Etoposide Carboplatine Ifosfamide | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| Study of AMV564 in Patients With AML | NCT03144245 | Acute Myeloid L... | AMV564 AMV564 in combi... | 18 Years - | Amphivena Therapeutics, Inc. | |
| Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma | NCT02482532 | Melanoma | tvs-CTL Vaccine | 18 Years - 66 Years | University of Kansas Medical Center | |
| VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma | NCT01830465 | Non Hodgkin's F... | Bortezomib (VEL... Rituximab | 18 Years - 90 Years | Gruppo Italiano Studio Linfomi | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | NCT01423032 | Chronic Lymphoc... | bendamustine Fludarabine | 18 Years - | WiSP Wissenschaftlicher Service Pharma GmbH | |
| Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | NCT00651781 | Acute Myeloid L... | Bortezomib | 18 Years - | PETHEMA Foundation | |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | NCT03742245 | Breast Cancer M... Breast Cancer | Olaparib Vorinostat | 18 Years - | The Methodist Hospital Research Institute | |
| Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | NCT05238311 | Multiple Myelom... | Elranatamab | 18 Years - | Pfizer | |
| Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | NCT03179930 | Lymphoma Relapsed Refractory | Entinostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts | NCT03160079 | B-Cell Acute Ly... | blinatumomab pembrolizumab | 18 Years - | University of California, San Diego | |
| Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | NCT00635557 | Glioblastoma Mu... | MPC-6827 + Carb... | 18 Years - | Myrexis Inc. | |
| Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies | NCT02795182 | Lymphoma Leukemia | Zanubrutinib Tislelizumab | 18 Years - | BeiGene | |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | NCT01695330 | Multiple Myelom... | Subcutaneous bo... | 18 Years - | Oncotherapeutics | |
| An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma | NCT01969695 | Non-Hodgkin's L... | ABT-199 | 18 Years - 99 Years | AbbVie | |
| Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL | NCT00385125 | Lymphoma, High-... | Bendamustine Rituximab | 18 Years - | University of Magdeburg | |
| Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT01359657 | Multiple Myelom... | Anti-CXCR4 (BMS... Lenalidomide Dexamethasone Anti-CXCR4 (BMS... Bortezomib Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia | NCT03630042 | Waldenstrom Mac... | Pembrolizumab Rituximab | 18 Years - | University College, London | |
| Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | NCT02298166 | Acute Myeloid L... | chemotherapy (M... Placebo Crenolanib Allogeneic stem... | 18 Years - | University of Ulm | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | NCT05595447 | Hodgkin Lymphom... Refractory Hodg... Relapsed Hodgki... | Brentuximab Ved... | 15 Years - 90 Years | Hospital Regional de Alta Especialidad del Bajio | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | NCT01324180 | Acute Lymphobla... | Metformin Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Intrathecal che... | 1 Year - 30 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| MMRF Molecular Profiling Protocol | NCT02884102 | Multiple Myelom... Plasma Malignan... | genetic sequenc... | 18 Years - | Multiple Myeloma Research Foundation | |
| Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia | NCT02353143 | Recurrent Adult... Acute Myeloid L... | MEN1112 | 18 Years - | Menarini Group | |
| Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | NCT02800889 | Lymphoma Solid Tumor (Ex... | Pixantrone | 6 Months - 21 Years | CTI BioPharma | |
| Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | NCT01241162 | Neuroblastoma Ewings Sarcoma Osteogenic Sarc... Rhabdomyosarcom... Synovial Sarcom... | Autologous dend... | 1 Year - 24 Years | University of Louisville | |
| Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | NCT03661515 | Acute Myeloid L... | Selinexor fludarabine idarubicin cytarabine G-CSF | 18 Years - 65 Years | PETHEMA Foundation | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | NCT02499081 | Multiple Myelom... | Ixazomib | 18 Years - 75 Years | University of Arkansas | |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | NCT03422523 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | Atezolizumab Rituximab Gemcitabine 100... Oxaliplatin 100... | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 | NCT01969669 | Non-Hodgkin's L... | ABT-199 Ketoconazole | 18 Years - 99 Years | AbbVie | |
| Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT02187133 | Lymphoma, Non-H... Lymphoma | Carfilzomib Bendamustine Rituximab | 18 Years - | University of California, San Francisco | |
| A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies | NCT04011293 | Relapsed or Ref... | CNCT19 | 18 Years - | Shandong University | |
| Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | NCT02356458 | Mantle Cell Lym... | Ibrutinib bortezomib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | NCT02631252 | Leukemia, Acute... | Hydroxychloroqu... Mitoxantrone Etoposide | 18 Years - 80 Years | University of Pittsburgh | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | NCT05748197 | Acute Myeloid L... | ADCLEC.syn1 CAR... Conditioning ch... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | NCT06215118 | Multiple Myelom... | Elranatamab Iberdomide | 18 Years - | Pfizer | |
| Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | NCT00511238 | Multiple Myelom... | carfilzomib carfilzomib | 18 Years - | Amgen | |
| Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | NCT00928200 | Relapsed Acute ... Allergy to PEG ... Allergy to Nati... | Erwinase Vincristine Dexamethasone Doxorubicin Cytarabine Methotrexate Triple Intrathe... Dexrazoxane | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | NCT01460901 | Neuroblastoma | GD2 CAR modifie... | 18 Months - 17 Years | Children's Mercy Hospital Kansas City | |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | NCT06421675 | Refractory Mult... | Elranatamab inj... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders | NCT00071396 | Chronic Lymphoc... | Campath-1H Rituximab | 15 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
